Oruka Therapeutics (NASDAQ:ORKA) Stock Price Expected to Rise, Barclays Analyst Says

Oruka Therapeutics (NASDAQ:ORKA) had its price objective upped by stock analysts at Barclays from $48.00 to $50.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s target price would suggest a potential upside of 25.00% from the stock’s previous close.

A number of other analysts also recently commented on ORKA. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, March 8th. Stifel Nicolaus increased their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research note on Thursday, November 13th. They set a “buy” rating and a $45.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Finally, Guggenheim restated a “buy” rating and issued a $60.00 target price on shares of Oruka Therapeutics in a research report on Friday. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and an average price target of $56.67.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $40.00 on Friday. Oruka Therapeutics has a one year low of $5.49 and a one year high of $41.19. The stock’s fifty day moving average is $32.92 and its 200-day moving average is $27.59. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -21.51 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.16. Analysts forecast that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Insider Buying and Selling

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the sale, the insider directly owned 34,018 shares of the company’s stock, valued at approximately $1,101,162.66. This represents a 17.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 21,000 shares of company stock valued at $663,530 in the last quarter. 24.69% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently made changes to their positions in the business. Royal Bank of Canada grew its stake in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics during the fourth quarter valued at approximately $37,000. PNC Financial Services Group Inc. acquired a new stake in Oruka Therapeutics during the third quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd bought a new stake in Oruka Therapeutics during the fourth quarter worth approximately $67,000. Finally, Russell Investments Group Ltd. bought a new stake in Oruka Therapeutics during the third quarter worth approximately $43,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics News Summary

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.